

REMARKS

Claims

A listing of the pending claims 1-25 is provided herein. Claims 1-12, 16-19, and 23-25 have been withdrawn as drawn to a non-elected invention. The claims have not been amended.

Restriction Requirement

With respect to the restriction requirement, Applicants hereby elect with traverse Group II, allegedly drawn to a method of modulating a p21 pathway of a cell by contacting the cell with a small molecule that binds to a ROR polypeptide or nucleic acid, for prosecution on the merits. The claims readable thereon are claims 13-15 and 20-22.

With respect to the species restriction requirement, Applicants hereby elect with traverse, SEQ ID NO: 14 for nucleic acid and SEQ ID NO: 18 for polypeptide, for prosecution on the merits. The claims readable thereon are claims 13-15 and 20-22.

Claims 13-15 and 20-22 are generic with respect to the elected species. As stated in the Restriction Requirement, upon allowance of a generic claim Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all of the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Conclusion

If the Examiner has any questions regarding this response, he is invited to call the undersigned attorney.

Respectfully submitted,

Dated: February 22, 2008

/Anita J. Terpstra/
Anita J. Terpstra, Ph.D.
Registration No. 47,132

McDonnell, Boehnen,
Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001